Navigation Links
EDP Biotech Takes Next Step in the Development of ColoMarker
Date:12/14/2009

KNOXVILLE, Tenn., Dec. 14 /PRNewswire/ -- Embarrassing and sometimes uncomfortable colonoscopies may soon be a thing of the past. National researchers are taking note of a new screening test that is making its way through the approval process. The Knoxville-based company, EDP Biotech Corporation (EDP) is pursuing a patent for the revolutionary, ColoMarker, an affordable medical device doctors can use to screen for colon cancer with only a blood sample. "When you consider that 30% of colon cancer deaths are avoidable by early screening, the need for a product like ColoMarker is there," says Kevin Jones, Ph.D., Chief Scientific Officer of EDP.

National researchers who study colorectal cancer are closely monitoring emerging technologies, like ColoMarker. Their findings are encouraging; just last week, the Cancer Society, the National Cancer Institute, the Centers for Disease Control and Prevention and the North American Association of Central Cancer Registries released an optimistic report about the expected decline in deaths from colon cancer.

According to the study, the prediction is based on emerging methods for better screening and treatment. The scientists at EDP Biotech say that ColoMarker, screening statistics could soar and the numbers of deaths from colon cancer could plummet. "ColoMarker could lead to a radical shift in the way we detect and treat colon cancer," says Jones.

In pre-clinical trials, ColoMarker detected a very high percentage of stages I, II, and III colon cancers in people with the disease. The ColoMarker test looks for a substance in blood called CA1-18.

In tests of 2,370 blood samples, ColoMarker showed an overall accuracy rate for detecting colon cancer of 93%. In another early trial, researchers tested for the presence of ColoMarker in 243 blood samples from patients who had symptoms of colon cancer. They compared the results of these blood tests to results from the Fecal Occult Blood Test (FOBT). ColoMarker had a false positive rate of 11% compared with a false positive rate of 30% for FOBT. This means that ColoMarker is much less likely to identify people as having colon cancer, when they do not have the disease. In this same group of 243 patients, ColoMarker detected 100% of Stage I (early stage) colon cancers, while FOBT identified only about 40% of early stage disease.

The patenting process for ColoMarker is underway and Jones says the company is preparing for clinical trials in the Federal Drug and Administration regulatory approval process. Jones is confident that ColoMarker could save billions of dollars in healthcare costs, but more importantly he says, "We want to move expeditiously to get ColoMarker approved so we can be apart of saving tens of thousands of lives." For more information on the ColoMarker, visit EDP's website at www.edpbiotech.com.

About EDP Biotech Corporation

EDP Biotech Corporation (EDP) is a medical device company focused on the development and sale of immunodiagnostic tests for both humans and animals. EDP utilizes more than 30 years of research and development in identification and purification of proteins present in the early stages of biological changes for production of in vitro diagnostic tests whose primary target is Early Detection Products.

SOURCE EDP Biotech Corporation


'/>"/>
SOURCE EDP Biotech Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune to Present at Deutsche Bank Biotech Confab
2. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
3. Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting
4. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
5. Howard Goldstein Joins Microchip Biotechnologies, Inc. as Executive Vice President
6. Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotechs New Psoriasis Agent Stelara (ustekinumab) is High
7. Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference
8. Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results
9. Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon
10. Biotechnology Salutes Americas Veterans; Innovations Continue to Offer Improved Treatment and Care of Combat Troops
11. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
(Date:4/19/2017)... 2017  New research provides evidence that an old drug ... a study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... Parkinson,s disease, the oral drug levodopa has long been considered ... as the disease progresses, the effects of the medication can ...
(Date:4/18/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical ... Gynecology markets with innovative and proprietary products, will release ... 2017 after the market close on Tuesday, May 2, ... conference call and webcast to discuss its financial results ... 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
Breaking Medicine Technology:
(Date:4/26/2017)... LOUIS (PRWEB) , ... April 26, 2017 , ... ... designed specifically to improve the profitability of ready-to-drink, high-protein beverages by helping beverage ... economic alternative to dairy proteins, providing direct cost savings as well as more ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... proud to announce that it has received 510(k) clearance from the U.S. Food ... and the MyoCycle Pro. , Both devices are stationary cycling systems that use ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. , the ... This new addition to the Mirroring360 product family combines device screen mirroring with ... Pro enables educators, business professionals and individuals to stream or mirror app screens, ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... California, committed to raising awareness for Duchenne muscular dystrophy, and funding for ... CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President ... are preparing for how his administration could impact the employee benefits industry. James ... changes are most likely to make it through Congress. His discussion will focus ...
Breaking Medicine News(10 mins):